Just a quick note from the ED at UC Davis
We in PECARN are starting a clinical trial of TXA in children with hemorrhagic trauma. TXA has not yet been studied in this population, and we want to ensure its safety and efficacy before widespread use.
Nate Kuppermann and Daniel Nishijima for the PECARN TXA in Trauma Study Group
Nathan Kuppermann, MD, MPH
Professor, Departments of Emergency Medicine and Pediatrics
Bo Tomas Brofeldt Endowed Chair, Department of Emergency Medicine
University of California, Davis School of Medicine
Principal Investigator, PRIME Node, Pediatric Emergency Care Applied Research Network (PECARN)
Chair, Steering Committee, (global) Pediatric Emergency Research Networks (PERN)
[log in to unmask] <mailto:[log in to unmask]>
> On Dec 12, 2017, at 2:24 PM, Lisa drago <[log in to unmask]> wrote:
> Good Afternoon,
> Our MICU advisory council is requesting permission to use TXA in pediatric trauma patients in the prehospital setting. A few questions to help with this decision:
> Anyone using this in the pediatric patient in the prehospital setting?
> Anyone using this in other settings (trauma bay, OR, etc.) in pediatric patients?
> Anyone willing to share dosing or protocols?
> Thank you
> Lisa A. Drago, DO, FAAP
> Assistant Professor of Pediatrics and Emergency Medicine
> Cooper Medical School of Rowan University
> Pediatric Medical Director
> Division of EMS, Disaster, and Transport Medicine
> Department of Emergency Medicine
> Cooper University Hospital
> Camden, NJ 08103
> Phone: 856-342-2627
> Fax: 856-968-8272
> For more information, send mail to [log in to unmask] with the message: info PED-EM-L
> The URL for the PED-EM-L Web Page is:
For more information, send mail to [log in to unmask] with the message: info PED-EM-L
The URL for the PED-EM-L Web Page is: